Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 25Stomach Neoplasms 11Pancreatic Neoplasms 11Colonic Neoplasms 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Neoplasms 5Cholangiocarcinoma 5Burkitt Lymphoma 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Lung Neoplasms 2Leukemia, Biphenotypic, Acute 2Leukemia 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Urachal cancer 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1

Interventions

magrolimab 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Unresectable Colorectal Cancer × Leucovorin × Clear all
NCT06540261 2024-09-19

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
65 enrolled
Gastrointestinal

Unresectable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡